CATX

#3152
Perspective Therapeutics, Inc. Common Stock
3.1 2 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.07
3.12
Intervallo Annuale
1.96
6.16
Variazione giornaliera
-0.95%
Variazione Mensile
+7.22%
Variazione di 6 mesi
-37.85%
Variazione Annuale
-6.02%
Chiusura Precedente
3.1 5
Open
3.0 8
Minimo
3.0 7
Massimo
3.1 2
Volume
443
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Perspective Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K

Perspective Therapeutics, Inc. current report, Q3 FY2025

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Perspective Therapeutics, Inc. (NYSE American: CATX) on September 2, 2025. The report details corporate governance changes effective September 3, 2025, specifically the expansion of the Board of Directors and the appointment of a new director.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel and governance matters.

Material Changes

  • Board Expansion: The Board of Directors increased its size from five to six members.
  • New Appointment: Maya Martinez-Davis was appointed as a director, effective September 3, 2025.
  • Committee Assignments: Ms. Martinez-Davis was appointed to the Compensation Committee and the Nominations Committee.

Compensation and Governance Details

Ms. Martinez-Davis is eligible for the Company's Non-Employee Director Compensation Program, which includes:

  • Cash Retainer: $60,000 annually.
  • Equity Grant: An initial grant of 75,000 options to purchase common stock.
  • Valuation Cap: The grant date fair value of the options may not exceed $450,000.
  • Vesting Schedule: Options vest in 36 equal monthly installments, beginning one month after the grant date, contingent on continued service.

The Company expects Ms. Martinez-Davis to enter into a standard indemnification agreement. No undisclosed arrangements or conflicts of interest were reported.

Investor Verification Checklist

  • Verify the exact grant date and fair value of the 75,000 stock options issued to Ms. Martinez-Davis in subsequent filings.
  • Confirm the total number of outstanding options and shares authorized under the Company's equity incentive plans to assess dilution impact.
  • Review the Company's most recent 10-K or 10-Q for current cash reserves and burn rate, as this 8-K contains no liquidity data.
  • Monitor future press releases for updates on the Company's clinical pipeline or strategic direction following the board expansion.

Notizie